Humanized Mouse Models
Humanized mouse models are beneficial tools for immuno-oncology and infectious disease research. They have improved the ability to predict human responses to new therapeutics in clinical development.
Depending on research requirements, it is critical that researchers have the ability to obtain study-ready animals or maintain the option to humanize the mice in-house to meet their project timelines and study requirements.
|
|
|---|
|
When your research requires humanized animal models, Charles River offers multiple options, both founded on the NCG triple-immunodeficient mouse.* CD34+ Humanized Mouse Model * Available in North America only |
Advance Your Program with Humanized Mouse Models
Currently, the Charles River NCG triple-immunodeficient mouse model is the foundation for our humanization portfolio. Its unique phenotype allows it to host xenograft cells, tissue, and human immune system components. It displays noticeable improvements of foreign tissue transplantation and engraftment, compared to previous generations of immunocompromised mice.
The NCG mouse is best suited for studies on tumor biology, immuno-oncology, infectious diseases, graft-versus-host disease (GvHD), hematopoiesis, and tissue transplantation.
Charles River's expertise in oncology drug discovery, spanning from target identification to IND studies, makes us ideally suited to run your humanized mouse tumor model studies for you.
Charles River Hu-Mouse™ Models
We now have two options available for humanized mouse models, engrafted with either PBMC or CD34+ stem cells derived from umbilical cord blood. These models have been shown to respond to known immune checkpoint inhibitor therapies.
| CD34+ | PBMC |
|---|---|
| HSC derived from umbilical cord; multiple donors in each cohort. | A single cohort of animals can engraft with a single donor. |
| ~Week 15: > 25% huCD45 blood cells | Week 3: ~30% huCD45 blood cells |
| T cell focused | T cell focused |
| Long-term studies (no GvHD) | Short-term studies due to GvHD |
| Number of T cells may vary with multiple donors | GvHD onset varies with donor |
| Less costly approach |
The ability of human immune cells to engraft in the NCG mouse makes it a powerful tool to evaluate compounds for immuno-oncology, GvHD, infectious diseases, and inflammatory diseases.
|
to evaluate immune checkpoint therapeutics? |
|---|
|
Check out our scientific poster, Validation of Humanized PD-1 Knock-in Mice as an Emerging Model to Evaluate Human-Specific PD-1 Therapeutics, to learn more. |
Choose the option that's best for you:*
- Purchase study-ready HuCD34-NCG mice
- Purchase study-ready HuPBMC-NCG mice
- Create your own humanized model using our NCG/PBMC select humanization kit
* Available in North America only